| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
| Targets |
3-Sialyllactose acts as a prebiotic and immunomodulatory agent. It is not metabolized by human enzymes but can be utilized by certain beneficial gut bacteria, promoting the growth of Bifidobacteria and other commensals. The sialic acid moiety may also play a role in brain development and cognitive function by providing a source of sialic acid for ganglioside and glycoprotein synthesis. The compound may also have anti-adhesive properties by blocking pathogen binding to host cells.
|
|---|---|
| ln Vitro |
3'-Sialyllactose sodium (0-250 μ; 24-36 h) increases extracellular sulphated proteoglycan accumulation, Col2a1 synthesis, and inhibits the effects of inflammatory cytokines[1].
In chondrocytes, 3'-Sialyllactose sodium (0-250 μM; 24 h) activates Sox9 expression while suppressing NF-κB activation[1]. In all strains, regardless of whether metabolic activation is present or absent, 3'-Sialyllactose sodium (0-5000 μg/plate) exhibits no mutagenic effect and exhibits no discernible growth inhibition or deposition[3]. In the presence or absence of metabolic activation, 3'-Sialyllactose sodium (1250 μg/mL) does not cause chromosomal aberrations and exhibits non-clastogenic effects[3]. 3-Sialyllactose exhibits prebiotic activity by promoting the growth of beneficial gut bacteria, particularly Bifidobacteria. It may have immunomodulatory effects by influencing cytokine production and immune cell function. The compound's sialic acid content may support neurodevelopment. In vitro studies have shown that 3-sialyllactose can inhibit the adhesion of pathogens to intestinal epithelial cells. However, specific IC50 or EC50 values are not typically reported for this compound. |
| ln Vivo |
3'-Sialyllactose sodium (10-100 mg/kg; p.o. three times a week for 6 weeks) protects mice from osteoarthritis-induced cartilage destruction[1].
Inducing micronuclei in mouse bone marrow cells with 3'-sialyllactose sodium (500, 1000, and 2000 mg/kg; oral administration; once) does not work[3]. The maximum tolerated dose (MTD) for male and female beagle dogs is greater than 2000 mg/kg, according to 3'-Sialyllactose sodium (oral administration; (500 to 1000 to 2000 mg/kg) every dose at 4-day intervals[3]. The highest dose tested for 3'-sialyllactose sodium (LD50) is above 20 g/kg bw[3]. In vivo, 3-sialyllactose has been studied for its effects on gut microbiota composition, immune function, and neurodevelopment in animal models and human infants. It promotes the growth of beneficial bacteria in the gut, which may contribute to improved gastrointestinal health and immune function. The compound's sialic acid content may support brain development. However, detailed in vivo efficacy data are limited as it is primarily a nutritional component rather than a therapeutic drug. |
| Enzyme Assay |
The activity of 3-sialyllactose is assessed in vitro using bacterial culture assays to measure its prebiotic effects. Bifidobacteria or other gut bacteria are cultured in media containing 3-sialyllactose as the sole carbon source, and bacterial growth is monitored. Pathogen adhesion inhibition assays are performed using intestinal epithelial cells and pathogenic bacteria. Immune modulation is assessed by measuring cytokine production in immune cell cultures.
|
| Cell Assay |
Cell-based assays for 3-sialyllactose typically employ intestinal epithelial cells (e.g., Caco-2 cells) or immune cells. Cells are treated with 3-sialyllactose, and various parameters are measured: barrier function (TEER), cytokine production (ELISA), and pathogen adhesion inhibition. The compound's effects on cell viability are assessed using standard assays. The compound's prebiotic effects are assessed in co-culture systems with gut bacteria.
|
| Animal Protocol |
8-week-old male C57BL/6 mice with medial meniscus surgery[1]
10, 50 and 100 mg/kg Oral gavage; 10-100 mg/kg three times a week; for 6 weeks In vivo studies with 3-sialyllactose are typically performed in animal models (rodents, piglets) or in human clinical trials. The compound is administered orally via diet or gavage. Gut microbiota composition is analyzed by 16S rRNA sequencing. Immune parameters are measured in blood and tissues. Neurodevelopmental outcomes are assessed by behavioral tests and brain tissue analysis. The compound is generally considered safe for consumption. |
| ADME/Pharmacokinetics |
3-Sialyllactose sodium has molecular formula C23H38NNaO19 (approximate) and molecular weight around 655.5 (sodium salt). It has CAS number 128596-80-5. The compound is a white to off-white powder and is soluble in water. It should be stored at -20°C for long-term stability. The compound is a research-grade reagent for studying human milk oligosaccharides.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-sialyllactose are limited as it is a naturally occurring compound found in human milk. It is generally recognized as safe (GRAS) for consumption in infants and adults. No significant toxicity has been reported at physiological concentrations. The compound should be handled with standard laboratory safety precautions.
|
| References |
|
| Additional Infomation |
3-Sialyllactose sodium is a sialylated human milk oligosaccharide (HMO) with an α-2,3 linkage between sialic acid and lactose. It is a naturally occurring compound found in human breast milk. 3-Sialyllactose has been studied for its prebiotic effects, immune modulation, and neurodevelopmental support. It is used as a research reagent for studying gut microbiota, infant nutrition, and immune function.
|
| Molecular Formula |
C23H38NNAO19
|
|---|---|
| Molecular Weight |
655.5329
|
| Exact Mass |
655.193
|
| CAS # |
128596-80-5
|
| Related CAS # |
128596-80-5
|
| PubChem CID |
71308479
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
44
|
| Complexity |
934
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
[Na+].O1[C@@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O[H])O[H])[C@@]([H])([C@]([H])(C([H])([H])[C@@]1(C(=O)[O-])O[C@]1([H])[C@]([H])([C@]([H])(O[C@]([H])([C@@]([H])(C([H])([H])O[H])O[H])[C@@]([H])([C@]([H])(C([H])=O)O[H])O[H])O[C@]([H])(C([H])([H])O[H])[C@]1([H])O[H])O[H])O[H])N([H])C(C([H])([H])[H])=O
|
| InChi Key |
LTWFUJWFLMHANB-YZMHZYKKSA-M
|
| InChi Code |
InChI=1S/C23H39NO19.Na/c1-7(29)24-13-8(30)2-23(22(38)39,42-19(13)15(35)10(32)4-26)43-20-16(36)12(6-28)40-21(17(20)37)41-18(11(33)5-27)14(34)9(31)3-25;/h3,8-21,26-28,30-37H,2,4-6H2,1H3,(H,24,29)(H,38,39);/q;+1/p-1/t8-,9-,10+,11+,12+,13?,14+,15+,16-,17+,18+,19+,20-,21-,23-;/m0./s1
|
| Chemical Name |
sodium;(2S,4S,6R)-5-acetamido-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate
|
| Synonyms |
3'-Sialyllactose sodium; 3'-SL sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~381.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5255 mL | 7.6274 mL | 15.2548 mL | |
| 5 mM | 0.3051 mL | 1.5255 mL | 3.0510 mL | |
| 10 mM | 0.1525 mL | 0.7627 mL | 1.5255 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
